Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein SA pseudogene 23 (RPSAP23) is one of several processed pseudogenes derived from the ribosomal protein SA (RPSA) gene, which encodes a multifunctional ribosomal protein that also serves as a laminin receptor in humans[3][5][7]. Pseudogenes such as RPSAP23 typically result from retrotranspositional events and lack the capacity to produce functional proteins. While the full-length RPSA protein is involved in ribosome structure and has roles in cell surface interactions relevant to cancer progression and infective mechanisms, the pseudogene RPSAP23 does not have a confirmed biological function, is not a therapeutic target, and is not associated with known disease phenotypes or drug interactions[3][5][7]. Most research on RPSA pseudogenes focuses on their potential regulatory roles as non-coding RNAs, but there is no evidence that RPSAP23 is functionally significant. In summary: RPSAP23 is not a functional target, receptor, or protein; it is a non-coding pseudogene with no established clinical or biological role[5][7].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein SA pseudogene 23 (RPSAP23).